NewsRx

Search our medical news database

Colorectal Cancer

Use of germline DNA pharmacogenetics to study colorectal tumor DNA validated

Published in Drug Week, February 17th, 2006

The use of germline DNA pharmacogenetics to study colorectal tumor DNA was validated.

"Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype," investigators in the United States reported.

"To date, there has been little attention paid to defining the relationship between tumor and germline genomes. This study compared 28 polymorphisms in 13 genes of high importance to cancer pharmacogenetics from 10 different chromosome regions, in DNA from normal mucosa and colon tumors in 44 paired...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook